NCT07305298

Mirabegron in Patients With Age-Related Macular Degeneration

Mirabegron in Patients With Age-Related Macular Degeneration Treated for Overactive Bladder: A Study Protocol for a Non-Randomized Prospective Controlled Trial

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 312 (estimated)
• Sponsor: University of Naples · Academic / Other
• Sex: All
• Age: 50 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if Mirabegron works to treat dry AMD in patients, aged between 50 and 80 years-old, with early or moderate dry AMD and overactive bladder. The main question it aims to answer is: • Is there any change in outer retina morphology in patients treated? Researchers will compare the safety and efficacy of mirabegron versus conventional approach (Solifenacin) to treat dry AMD in patients with dry AMD and overactive bladder. Participants will: * Take Mirabegron or Solifenacin every day for 12 months * Visit the clinic once every 6 months for checkups and tests

Conditions

• Dry AMD
• Overactive Bladder

Interventions

Type	Name	Description
DRUG	Mirabegron 50mg	Mirabegron (50mg/day per os) will be administered in patients with dry AMD and overactive bladder (MMirabegron arm)
DRUG	Solifenacin 5mg	Solifenacin (5mg/day per os) will be administered in control group (dry amd and overactive bladder)

Timeline

• Start date: 2026-04-01
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2025-12-26
• Last updated: 2026-02-06

Locations

1 site across 1 country: Italy